ARK Genomic Revolution ETF ARKG

ARKG es un ETF gestionado activamente que busca un crecimiento a largo plazo del capital invirtiendo, en circunstancias normales, principalmente (al menos el 80% de sus activos) en valores de renta variable extranjera negociados en bolsa, tanto nacionales como estadounidenses, de empresas de diversos sectores, incluyendo cuidado de la salud, tecnología de la información, materiales, energía y bienes de consumo discrecional, que son relevantes para el tema de inversión del Fondo de la revolución genómica.

• The Motley Fool 31 ago

  Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  Cathie Wood's Ark Invest added to positions in Nvidia, Broadcom, and Intellia Therapeutics on Friday as these stocks declined. Nvidia exceeded earnings expectations with 106% revenue growth and raised guidance to 70% for fiscal 2028, now trading at 14x forward earnings. Broadcom is on track for accelerating growth with an upcoming earnings report. Intellia, a gene-editing biotech, has declined over 50% from recent highs but remains well-funded with analyst support.

  

• The Motley Fool 22 jul

  Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

  Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.

  

• The Motley Fool 19 jul

  Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?

  Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.

  

• Benzinga 27 ene

  Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops

  CRISPR Therapeutics AG, a major holding in Cathie Wood's ARK funds, faces significant headwinds as its momentum score plummeted from 76.81 to 50.97 following a 10% stock decline. The decline was triggered by CEO insider share sales exceeding 90,000 shares and disappointing Q3 revenue of just $890,000, far below the $8.06 million consensus estimate, signaling weak product adoption.

  

• Benzinga 22 ene

  FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

  The FDA approved Guardant Health's Guardant360 CDx blood test as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Pfizer's Braftovi treatment combined with cetuximab and chemotherapy. This marks the 25th companion diagnostic indication for the platform and expands non-invasive genomic testing access. Guardant Health stock surged 2.27% to $118.37, trading at a 52-week high with strong technical momentum.